書誌事項
- タイトル別名
-
- Laboratory and clinical studies of NM441 in respiratory tract infections
この論文をさがす
抄録
We examined NM441, a new developed new-quinolone antimicrobial, for its pharmacokinetics in theserum and sputum, and for its clinical efficacy in respiratory tract infections. The results were as follows.<BR>1) Antimicrobial activity<BR>The minimal inhibitory concentrations (MICs) of NM394, the active form of NM441, were measured for741 clinically isolated strains of 18 species of bacteria (including gram-positive cocci, Moraxella catarrhalis, gram-negative bacilli and Bacteroides fragilis), and compared with those of ofloxacin (OFLX), lomeflo-xacin (LFLX) and tosufloxacin (TFLX). NM394 showed lower activity than TFLX, but higher than LFLX.And it was equal to or more powerful than OFLX.<BR>2) Serum and sputum levels<BR>Serum and sputum concentrations of NM394 were studied in a patient with seconday bronchitis aftermultiple oral administration of 200mg of NM441 twice daily for 7 days. The maximum serum level was1.12μg/ml, and the maximum sputum level was 0.35μg/ml.<BR>3) Clinical results<BR>200mg of NM441 twice daily was given 3 patients with respiratory tract infections for 7 or 11 days. Clinical efficacy was as good in 2 cases and fair in 1 case. No subjective or objective side effects and noabnormalities in laboratory values were observed.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 44 (Supplement1), 350-355, 1996
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001206290127360
-
- NII論文ID
- 10007601610
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可